The Food and Drug Administration's Deliberations on Antidepressant Use in Pediatric Patients
Citation
Leslie, Laurel K., Thomas B. Newman, P. Joan Chesney, and James M. Perrin. 2005. “The Food and Drug Administration’s Deliberations on Antidepressant Use in Pediatric Patients.” PEDIATRICS 116 (1) (July 1): 195–204. doi:10.1542/peds.2005-0074.Abstract
On February 2, 2004, the Food and Drug Administration organized a joint meeting of the Neuro-Psychopharmacologic Advisory Committee and Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee to examine the occurrence of suicidality in clinical trials that investigate the use of the newer anti-depressant drugs in pediatric patients. Committee members reconvened on September 13–14, 2004, and concluded that there was a causal link between the newer antidepressants and pediatric suicidality. This article provides a summary of the Food and Drug Administration deliberations for the pediatric clinician. We also provide research, regulation, education, and practice implications for care for children and adolescents who may be eligible for treatment with these medications.Other Sources
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1550709/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:30207961
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)